127 related articles for article (PubMed ID: 27789081)
1. Use of drugs against osteoporosis in the Baltic countries during 2010-2014.
Laius O; Maasalu K; Kõks S; Märtson A
Medicina (Kaunas); 2016; 52(5):315-320. PubMed ID: 27789081
[TBL] [Abstract][Full Text] [Related]
2. Trends in and relation between hip fracture incidence and osteoporosis medication utilization and prices in Estonia in 2004-2015.
Laius O; Pisarev H; Maasalu K; Kõks S; Märtson A
Arch Osteoporos; 2017 Dec; 12(1):48. PubMed ID: 28497319
[TBL] [Abstract][Full Text] [Related]
3. Anti-osteoporotic treatments in France: initiation, persistence and switches over 6 years of follow-up.
Belhassen M; Confavreux CB; Cortet B; Lamezec L; Ginoux M; Van Ganse E
Osteoporos Int; 2017 Mar; 28(3):853-862. PubMed ID: 27766368
[TBL] [Abstract][Full Text] [Related]
4. Gender inequalities in the treatment of osteoporosis.
Bor A; Matuz M; Gyimesi N; Biczók Z; Soós G; Doró P
Maturitas; 2015 Feb; 80(2):162-9. PubMed ID: 25433654
[TBL] [Abstract][Full Text] [Related]
5. Impact of the World Health Organization Pain Treatment Guidelines and the European Medicines Agency Safety Recommendations on Nonsteroidal Anti-Inflammatory Drug Use in Lithuania: An Observational Study.
Kasciuškevičiūtė S; Gumbrevičius G; Vendzelytė A; Ščiupokas A; Petrikonis K; Kaduševičius E
Medicina (Kaunas); 2018 May; 54(2):. PubMed ID: 30344261
[No Abstract] [Full Text] [Related]
6. Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.
Xu LH; Adams-Huet B; Poindexter JR; Maalouf NM
Osteoporos Int; 2016 May; 27(5):1701-8. PubMed ID: 26642963
[TBL] [Abstract][Full Text] [Related]
7. Osteoporosis drugs in real-world clinical practice: an analysis of persistence.
Iolascon G; Gimigliano F; Orlando V; Capaldo A; Di Somma C; Menditto E
Aging Clin Exp Res; 2013 Oct; 25 Suppl 1():S137-41. PubMed ID: 24046038
[TBL] [Abstract][Full Text] [Related]
8. [Therapeutic practice of bisphosphonate use and related pharmaceutical issues I].
Veszelyné Kotán E; Mészaros Á
Acta Pharm Hung; 2016; 86(1):13-22. PubMed ID: 27295873
[TBL] [Abstract][Full Text] [Related]
9. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
Ettinger MP
Arch Intern Med; 2003 Oct; 163(18):2237-46. PubMed ID: 14557222
[TBL] [Abstract][Full Text] [Related]
10. Effects of switching weekly alendronate or risedronate to monthly minodronate in patients with rheumatoid arthritis: a 12-month prospective study.
Ebina K; Noguchi T; Hirao M; Hashimoto J; Kaneshiro S; Yukioka M; Yoshikawa H
Osteoporos Int; 2016 Jan; 27(1):351-9. PubMed ID: 26475289
[TBL] [Abstract][Full Text] [Related]
11. Secondary prevention of osteoporosis in Australia: analysis of government-dispensed prescription data.
Hollingworth SA; Gunanti I; Nissen LM; Duncan EL
Drugs Aging; 2010 Mar; 27(3):255-64. PubMed ID: 20210370
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Iwamoto J; Takeda T; Sato Y
Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
[TBL] [Abstract][Full Text] [Related]
13. [Bisphosphonate use and related pharmaceutical issues II].
Veszelyné Kotan E; Mészáros Á
Acta Pharm Hung; 2016; 86(1):23-34. PubMed ID: 27295874
[TBL] [Abstract][Full Text] [Related]
14. Prescription of alendronate and risedronate in men: off-label use in a health area.
León Vázquez F; Herrero Hernández S; Cuerpo Triguero C; Andrés Prado MJ; Cabello Ballesteros L
Reumatol Clin; 2015; 11(2):64-7. PubMed ID: 25107345
[TBL] [Abstract][Full Text] [Related]
15. Variations in osteoporosis medication utilization. A population-based ecological cross-sectional study in the region of Valencia, Spain.
Sanfélix-Gimeno G; Juliá-Sanchis ML; Librero J; Peiró S; García-Sempere A
PLoS One; 2018; 13(6):e0199086. PubMed ID: 29927952
[TBL] [Abstract][Full Text] [Related]
16. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.
Rosen CJ; Hochberg MC; Bonnick SL; McClung M; Miller P; Broy S; Kagan R; Chen E; Petruschke RA; Thompson DE; de Papp AE;
J Bone Miner Res; 2005 Jan; 20(1):141-51. PubMed ID: 15619680
[TBL] [Abstract][Full Text] [Related]
17. Treatment of osteoporosis in women intolerant of oral bisphosphonates.
Aspray TJ; Francis RM
Maturitas; 2012 Jan; 71(1):76-8. PubMed ID: 22079368
[TBL] [Abstract][Full Text] [Related]
18. [Bisphosphonates first-line pharmacological treatment].
Wallander M; Ljunggren Ö; Lorentzon M
Lakartidningen; 2016 Nov; 113():. PubMed ID: 27824394
[No Abstract] [Full Text] [Related]
19. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
[TBL] [Abstract][Full Text] [Related]
20. Treatment of osteoporosis after alendronate or risedronate.
Eiken P; Vestergaard P
Osteoporos Int; 2016 Jan; 27(1):1-12. PubMed ID: 26438307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
